TScan Therapeutics
(NASDAQ) TCRX
TScan Therapeutics Financials at a Glance
Market Cap
$60.12M
Revenue (TTM)
$9.14M
Net Income (TTM)
-$124.31M
EPS (TTM)
-$0.96
P/E Ratio
-0.96
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$0.93
Volume
447,810
Open
$0.91
Price
$0.93
Volume
447,810
Open
$0.91
Previous Close
$0.92
Daily Range
$0.87 - $0.93
52-Week Range
$0.85 - $2.57
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$0.93
Volume
447,810
Open
$0.91
Previous Close
$0.92
Daily Range
$0.87 - $0.93
52-Week Range
$0.85 - $2.57
Estimated Earnings Date
Aug 11, 2026
TCRX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout TScan Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
139
CEO
Gavin MacBeath, PhD
Website
www.tscan.comHeadquarters
Waltham, MA 02451, US
TCRX Financials
Key Financial Metrics (TTM)
Gross Margin
92%
Operating Margin
-14%
Net Income Margin
-14%
Return on Equity
-81%
Return on Capital
-71%
Return on Assets
-62%
Earnings Yield
-1.04%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$60.12M
Shares Outstanding
65.35M
Volume
447.81K
Avg. Volume
804.12K
Financials (TTM)
Gross Profit
$7.46M
Operating Income
-$135.81M
EBITDA
-$124.13M
Operating Cash Flow
-$135.32M
Capital Expenditure
-$4.41M
Free Cash Flow
-$139.73M
Cash & ST Invst.
$152.41M
Total Debt
$94.14M
TScan Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$982.00K
-54.8%
Gross Profit
$289.00K
-86.7%
Gross Margin
29.43%
N/A
Market Cap
$60.12M
N/A
Market Cap/Employee
$300.61K
N/A
Employees
200
N/A
Net Income
-$28.67M
+16.0%
EBITDA
-$27.28M
+16.7%
Quarterly Fundamentals
Total Cash
$128.06M
-49.1%
Total Debt
$92.54M
-4.6%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$85.10M
-7.6%
Short Term Debt
$7.44M
+49.6%
Return on Assets
-61.54%
N/A
Return on Invested Capital
-70.71%
N/A
Free Cash Flow
-$24.35M
+37.8%
Operating Cash Flow
-$24.28M
+35.4%